Scott L. Friedman Joins Scholar Rock's SAB
This article was originally published in Scrip
Scholar Rock, a company focused on drugs targeting growth factors in the disease microenvironment, has appointed fibrosis expert Scott L. Friedman to its scientific advisory board (SAB). Friedman is professor of medicine, dean for therapeutic discovery and chief of the division of liver diseases at the Icahn School of Medicine at Mount Sinai Hospital. He has also previously undertaken research into the underlying causes of fibrosis linked to chronic liver disease. Friedman has received various awards for his work including the China Friendship Award in 2014, the International Achievement Prize of the Europe Association for the Study of Liver Diseases in 2012 and the Hans Popper International Liver Research Prize in 2003.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.